André Scheen - Publications, H-index & Citations

André Scheen

universite clermont auvergne

81H指数

1.5K论文数

3.7W被引数

收录论文 139

发表时间

Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease-the ACTIDIANE randomized controlled trial 高强度身体活动与常规咨询对高风险肾脏疾病2型糖尿病患者肾功能下降的影响——ACTIDIANE随机对照试验

DIABETES & METABOLISM

IF4.7

2026-07-01

PREAI

Hadjadj, Samy; Ragot, Stephanie; Durocher, Lisa; Bigot-Corbel, Edith; Kessler, Laurence; Tauveron, Igor; Vidal-Trecan, Tiphaine; Saulnier, Pierre Jean; Gourdy, Pierre; Moret, Myriam; Rigalleau, Vincent; Borot, Sophie; Ducluzeau, Pierre Henri; Ciangura, Cecile; Paquot, Nicolas; Vambergue, Anne; Chevaliers, Nicolas; Carette, Claire; Monier, Arnaud; Bohme, Philip; Pernfornis, Alfred; Verges, Bruno; Morcel, Pierre; Gautier, Jean Francois; Halimi, Jean-Michel; Henrya, Patrick; Marre, Michel; Scheen, Andre; Duclos, Martine; Bosquet, Laurent; Cariou, Bertrand

Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?SGLT2抑制剂对2型糖尿病患者的安全性：现状如何？

Expert Opinion on Drug Safety

IF3.1

2026-04-30

PREAI

André J. Scheen

GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations GLP-1衍生的疗法与肌肉减少症：呼吁特别关注高风险特殊人群

Diabetes & Metabolism

IF4.7

2025-10-14

PREAI

André J. Scheen

Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?Ecnoglutide，一种偏向性的GLP-1受体激动剂，是否为2型糖尿病管理的潜在新角色？

The Lancet Diabetes & Endocrinology

IF0

2025-08-22

PREAI

André J Scheen

Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes 老年2型糖尿病患者个性化抗糖尿病药物管理的进展

Expert Review of Clinical Pharmacology

IF3

2025-06-30

PREAI

A. J. Scheen

GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies GLP-1受体激动剂、身体成分、骨骼肌与肌少症风险：从动物模型中的前景发现到人类研究中的争议关注

Diabetes & Metabolism

IF4.7

2025-06-24

PREAI

André J. Scheen

Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect 胰高血糖素样肽-1受体激动剂与酒精使用障碍：一种新兴的意外有益效应

DIABETES OBESITY & METABOLISM

IF5.7

2025-05-13

PREAI

André J. Scheen PhD

Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists 减肥疗法和成瘾: 减肥手术后的风险增加，但GLP-1受体激动剂的风险降低

DIABETES & METABOLISM

IF4.7

2025-03-01

PREAI

Scheen, AJ

GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy

DRUGS

IF14.4

2024-09-28

PREAI

Scheen, Andre J.

Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-05-13

PREAI

Scheen, Andre J.

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

EXPERT REVIEW OF CLINICAL PHARMACOLOGY

IF3

2023-11-08

PREAI

Scheen, Andre J.

Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2023-08-29

PREAI

Scheen, Andre J.

Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation 与2型糖尿病患者心肾保护相关的降糖药物使用不足: 从延迟开始到过早停药

LANCET REGIONAL HEALTH-EUROPE

IF13

2023-06-01

OAAI

Scheen, Andre J.

Clinical pharmacology of antidiabetic drugs: What can be expected of their use?

PRESSE MEDICALE

IF3.4

2023-03-01

PREAI

Scheen, Andre J.

Leukocyte telomere length, allelic variations in related genes and risk of coronary heart disease in people with long-standing type 1 diabetes

CARDIOVASCULAR DIABETOLOGY

IF10.6

2022-10-11

OAAI

Sanchez, Manuel; Kannengiesser, Caroline; Hoang, Sophie; Potier, Louis; Fumeron, Frederic; Venteclef, Nicolas; Scheen, Andre; Gautier, Jean-Francois; Hadjadj, Samy; Marre, Michel; Roussel, Ronan; Mohammedi, Kamel; Velho, Gilberto

Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties 用糖尿病药物对抗心力衰竭: 对药代动力学和药效学特性的回顾

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

IF3.4

2022-08-02

PREAI

Scheen, Andre J.

When therapeutic drugs lead to diabetes

DIABETOLOGIA

IF10.2

2022-03-04

OAAI

Feve, Bruno; Scheen, Andre J.

Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria

CLINICAL KIDNEY JOURNAL

IF4.6

2021-06-11

OAAI

Delanaye, Pierre; Wissing, Karl Martin; Scheen, Andre J.

ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes

DIABETES CARE

IF16.6

2021-04-07

OAAI

Abouleka, Yawa; Mohammedi, Kamel; Carpentier, Charlyne; Dubois, Severine; Gourdy, Pierre; Gautier, Jean-Francois; Roussel, Ronan; Scheen, Andre; Alhenc-Gelas, Francois; Hadjadj, Samy; Velho, Gilberto; Marre, Michel

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy Secondary Analysis From the FOURIER Randomized Clinical Trial 使用Evolocumab抑制PCSK9减少接受他汀类药物治疗的代谢综合征患者心血管事件的有效性和安全性来自FOURIER随机临床试验的二次分析

JAMA CARDIOLOGY

IF14.1

2021-02-01

OAAI

Deedwania, Prakash; Murphy, Sabina A.; Scheen, Andre; Badariene, Jolita; Pineda, Armando Lira; Honarpour, Narimon; Keech, Anthony C.; Sever, Peter S.; Pedersen, Terje R.; Sabatine, Marc S.; Giugliano, Robert P.

研究方向